menu
    • menu
    [{"orgOrder":0,"company":"Lirum Therapeutics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Private Placement","leadProduct":"LX-101","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lirum Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Lirum Therapeutics \/ ThinkEquity","highestDevelopmentStatusID":"6","companyTruncated":"Lirum Therapeutics \/ ThinkEquity"},{"orgOrder":0,"company":"Lirum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"LX-101","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lirum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lirum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lirum Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Lirum Therapeutics

    Menu

    Lirum Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lirum Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Lirum Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LX-101,Methotrexate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lirum Announces Positive Data on LX-101 for IGF-Related Cancers at 2024 ESMO Congress

                            Details : LX-101, a novel clinical-stage targeted therapy directed to the insulin-like growth factor 1 receptor. It is being investigated in IGF-1R related malignancies and Thyroid eye disease.

                            Brand Name : LX-101

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 14, 2024

                            Lead Product(s) : LX-101,Methotrexate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lirum Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Lirum Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LX-101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : ThinkEquity

                            Deal Size : $7.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Lirum Therapeutics Announces Closing of $7 Million Private Placement of Common Stock

                            Details : Net proceeds will be used by Lirum primarily to advance its clinical and preclinical studies and development of lead candidate LX-101, for working capital, and to potentially expand its product candidate pipeline.

                            Brand Name : LX-101

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            February 08, 2023

                            Lead Product(s) : LX-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : ThinkEquity

                            Deal Size : $7.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth